Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseases

Authors

  • Cindy Alcarraz Instituto Nacional de Enfermedades Neoplásicas. Lima, Perú. Médico oncólogo
  • Johana Muñiz Instituto Nacional de Enfermedades Neoplásicas. Lima, Perú. médico residente de oncología
  • Luis Mas Instituto Nacional de Enfermedades Neoplásicas. Lima, Perú. Médico oncólogo
  • Mivael Olivera Instituto Nacional de Enfermedades Neoplásicas. Lima, Perú. Médico oncólogo
  • Zaida Morante Instituto Nacional de Enfermedades Neoplásicas. Lima, Perú. Médico oncólogo
  • Manuel Alvarez Instituto Nacional de Enfermedades Neoplásicas. Lima, Perú. médico cirujano ginecólogo oncólogo
  • Raul Mantilla Instituto Nacional de Enfermedades Neoplásicas. Lima, Perú. estadístico
  • Jhajaira Araujo Oncosalud, AUNA. Lima, Perú. biólogo
  • Joseph Pinto Oncosalud, AUNA. Lima, Perú. biólogo

DOI:

https://doi.org/10.17843/rpmesp.2018.351.3599

Keywords:

Ovarian neoplasms, Chemotherapy, Neoadjuvant therapy, Cytoreduction surgical procedures, Peru

Abstract

Objectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peruvian women treated with neoadjuvant chemotherapy with carboplatin (6 AUC mg/mL/min) and paclitaxel (80 mg/m2 weekly) followed by IDS, at the National Institute of Neoplastic Diseases during the 2010-2014 period. Results. The 41 patients who made it to the interval surgery had a median age of 59 years (range: 47-73 years). In 37 (90.2%) patients, high-grade serous adenocarcinoma histology was reported. Thirty-four (82.9%) achieved optimal cytoreduction and five (14.7%), a complete pathological response. Progression-free survival at one year and two years was 74.7% and 51.8%, respectively. Overall survival at one year and two years was 85.2% and 71.4%, respectively. The risk of progression and death was greater in patients without optimal cytoreduction and in patients with postsurgery levels of carcinoembryonic antigen 125 > 30 U/mL. Conclusions. Neoadjuvant therapy with dose-dense carboplatin and paclitaxel achieved an elevated frequency of optimal cytoreduction. The post-surgery levels of carcinoembryonic antigen 125 and optimal cytoreduction were independent factors of progression-free survival and overall survival.

Downloads

Download data is not yet available.

Published

2018-04-05

How to Cite

1.
Alcarraz C, Muñiz J, Mas L, Olivera M, Morante Z, Alvarez M, Mantilla R, Araujo J, Pinto J. Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseases. Rev Peru Med Exp Salud Publica [nternet]. 2018 Apr. 5 [cited 2023 Sep. 22];35(1):46-54. vailable from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/3599

Issue

Section

Original Article

Most read articles by the same author(s)